All the herein preclinical results provide unprecedented support for future clinical testing of CDK7-selective inhibitors in HNSCC patients, ultimately helping to fill the gap of lack of effective molecular-targeted treatments for this disease. Here, CDK7 is linked to head and neck squamous cell carcinoma.